| Deal value | $2M |
|---|---|
| Share of market cap | 1.0% |
| Share of annual revenue | 16.5% |
Key highlights
- Acquisition of NeuroAirmid Therapeutics for $2.4 million upfront cash payment
- Addition of HUNT1 (hNSC-01), a Phase 1b/2a stage candidate for Huntington’s Disease
- Assumption of a $3.1 million co-funding obligation for the ongoing REGEN4HD study
- Integration of the HUNT1 program into the proprietary AlloSCOPE 5D manufacturing platform
- Access to external funding through a $12 million CIRM award supporting clinical development
What Is the Deal?
Lineage Cell Therapeutics acquired all outstanding shares of NeuroAirmid Therapeutics in a deal closed concurrently with the signing of the purchase agreement on November 12, 2026. The acquisition brings the HUNT1 (hNSC-01) program into Lineage's portfolio, a pluripotent stem cell-derived therapy currently in a Phase 1b/2a clinical trial for Huntington’s Disease. Under the terms, NeuroAirmid became a wholly owned subsidiary of Lineage. The deal also includes an exclusive license agreement with The Regents of the University of California for the underlying neural cell therapy technology used in the program.
Deal Structure & Terms
- Immediate cash payment of $2.4 million to NeuroAirmid stockholders at closing
- Assumption of a $3.1 million co-funding obligation toward the ongoing REGEN4HD study
- Acquisition includes rights to a $12 million CIRM grant issued in April 2026
- Lineage takes responsibility for future manufacturing and optimization activities
- The co-funding obligation is expected to be paid through February 2030
Strategic Rationale
“Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline. HUNT1 is a pluripotent stem cell derived, clinical-stage neural cell therapy program, with the potential to validate a new cell-based treatment modality for Huntington’s Disease.”
Financial Context
Lineage enters this acquisition with a market capitalization of approximately $250.5 million and a cash position of $32.4 million as of September 30, 2026. The company reported quarterly revenue of $1.1 million against a net loss of $4.8 million for the third quarter. Management indicates that current liquid assets are sufficient to support operations into the second quarter of 2028. The deal value of $2.4 million represents a disciplined capital allocation of less than 1% of the company's market value, aimed at diversifying the allogeneic cell transplant portfolio beyond its flagship OpRegen program.
Down 19.7% since our story on 12 Nov: $0.99 when we broke it → $0.80 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.95 |
|---|---|
| 20 Oct | $0.97 |
| 21 Oct | $0.95 |
| 22 Oct | $0.99 |
| 23 Oct | $1.00 |
| 26 Oct | $1.00 |
| 27 Oct | $1.03 |
| 28 Oct | $1.04 |
| 29 Oct | $1.03 |
| 30 Oct | $1.00 |
| 2 Nov | $1.01 |
| 3 Nov | $1.01 |
| 4 Nov | $1.03 |
| 5 Nov | $0.98 |
| 6 Nov | $1.02 |
| 9 Nov | $1.08 |
| 10 Nov | $1.04 |
| 11 Nov | $1.11 |
| 12 Nov | $0.99 |
| 13 Nov | $0.91 |
| 16 Nov | $0.80 |
Industry Landscape
The biotechnology sector is seeing increased consolidation around advanced cell therapies as companies seek to industrialize manufacturing processes. Huntington’s Disease remains a significant unmet medical need, characterized by the progressive degeneration of nerve cells in the brain. Lineage’s integration of HUNT1 into its AlloSCOPE 5D manufacturing platform reflects a broader industry trend of applying proprietary production technologies to specialized clinical assets. By leveraging a common cell line across multiple programs, firms aim to reduce the time and cost associated with scaling pluripotent cell-derived therapies for late-stage registrational trials.
Management commentary
“This transaction reflects the disciplined approach to capital allocation and strategic fit that we believe our investors have come to expect from Lineage. HUNT1 was created on the same proprietary cell line that Lineage uses and is compatible with its AlloSCOPE “5D” technology, providing us with a head start on our planned contributions.”
| Share price | $0.99 |
|---|---|
| Market cap | $250M |
| Revenue (annual) | $15M |
| 1-month price change | +8.82% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Lineage Cell Therapeutics, Inc. announcing the acquisition of NeuroAirmid Therapeutics, Inc.
Track Lineage Cell Therapeutics, Inc. live
Get the next Lineage Cell Therapeutics, Inc. SEC filing seconds after it lands.



